Form 4: Solid Biosciences Director Ian F. Smith Reports Stock Option Grant

Director Ian F. Smith reports the acquisition of stock options in Solid Biosciences Inc.

Summary

• On June 11, 2024, Ian F. Smith, a director of Solid Biosciences Inc., was granted stock options to purchase 34,400 shares of common stock.
• The exercise price of the options is $7.51 per share.
• The options vest in full on the earlier of the one-year anniversary of the grant date or immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.
• The options expire on June 11, 2034.

Sentiment

Score: 7

Explanation: The document reflects a routine grant of stock options, which is generally viewed as a positive sign of aligning management interests with shareholders. It's a neutral event with a slightly positive undertone.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants to directors are a standard practice across the biotechnology industry.
• Companies like Sarepta Therapeutics and BioMarin Pharmaceutical also utilize stock options as part of their compensation packages for directors and executives.
• The vesting schedule and exercise price are typical for such grants, aligning with industry norms.

Key Dates